Osprey Pharmaceuticals

Osprey Pharmaceuticals Ltd., a Montreal-based drug company focused on chronic diseases, has raised US$9 million in new funding. The deal includes $6 million in tranched convertible notes from GeneChem Therapeutics Venture Fund, Desjardins Capital Regional et Cooperatif, BDC Venture Capital and Western Technology Seed Investment Fund. It also included $3 million in venture debt from MMV Capital. www.ospreypharma.com